Rankings
▼
Calendar
TEVA
Teva Pharmaceutical Industries Limited
$36B
Q2 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.7B
-17.3% YoY
Gross Profit
$2.1B
43.8% margin
Operating Income
-$14M
-0.3% margin
Net Income
-$176M
-3.7% margin
EPS (Diluted)
$-0.17
QoQ Revenue Growth
-7.2%
Cash Flow
Operating Cash Flow
$162M
Free Cash Flow
$26M
Stock-Based Comp.
$47M
Balance Sheet
Total Assets
$67.0B
Total Liabilities
$47.7B
Stockholders' Equity
$17.9B
Cash & Equivalents
$1.9B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.7B
$5.7B
-17.3%
Gross Profit
$2.1B
$2.8B
-26.9%
Operating Income
-$14M
-$5.7B
+99.8%
Net Income
-$176M
-$6.0B
+97.1%
Revenue Segments
International Markets
$789M
71%
Other Activities
$321M
29%
Geographic Segments
North America
$1.9B
59%
Europe
$1.3B
41%
← FY 2018
All Quarters
Q3 2018 →
TEVA Q2 2018 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena